DMC&H launches CDC and Flow Crossmatch tests for kidney transplant patients

Ludhiana, July 19, 2025: The Department of Pathology at Dayanand Medical College & Hospital (DMCH), Ludhiana, proudly announces the inauguration of the state-of-the-art CDC (Complement Dependent Cytotoxicity) cross match and Flow Crossmatch testing facility today. The newly introduced tests are a breakthrough for kidney transplant patients, ensuring precise compatibility assessments and minimizing the risk of organ rejection. These tests will play a pivotal role in pre-transplant evaluations, helping clinicians make informed decisions for better patient outcomes.
The ceremony was presided over by Bipin Gupta, Secretary, DMC&H Managing Society, and  Mukesh Verma, Treasurer, DMC&H Managing Society, in the presence of senior faculty and medical dignitaries, Dr. GS Wander, Principal; Dr. Sandeep Kaushal, Dean Academics; Medical Superintendents Dr. Sandeep Sharma,Dr. Ashwani K Chaudhary, Dr. Bishav Mohan, Chief Cardiologist and Dr. Ashima Taneja, Additional Medical Superintendent, Dr. Bhavna Garg, Professor & Head, Department of Pathology along with all faculty members from Department of pathology, residents and medical staff.
Speaking on the occasion, Bipin Gupta highlighted that DMC&H is always committed to provide best medical care facilities to the general public. He further stressed DMC&H’s focus on integrating cutting-edge diagnostic technologies to deliver exceptional patient care.
Giving information about this facility, Dr. Bhavna Garg, Professor and Head of the Department of Pathology, highlighted the advantages of CDC (Complement-Dependent Cytotoxicity) and Flow Crossmatch tests in transplant compatibility assessments. She explained that these advanced tests offer higher accuracy by detecting even minor antibody reactions, thereby reducing the risk of transplant rejection. With faster turnaround times, they enable quicker pre-transplant evaluations, improving patient safety by minimizing post-transplant complications. Additionally, these tests enhance organ matching, leading to better success rates for kidney transplants. Utilizing cutting-edge immunological technology, the facility ensures reliable and sensitive results, reinforcing its commitment to improving transplant outcomes and patient care.
Further she explained the clinical significance of these tests in transplant immunology, stating that they will greatly benefit end-stage renal disease (ESRD) patients awaiting kidney transplants. The quick results will help patients avail the facility of cadaveric renal transplant.